BARCELONA – Two genomics-centered trials in the Netherlands — the Center for Personalized Cancer Treatment (CPCT-02) and Drug Rediscovery Protocol (DRUP) — are demonstrating the potential for finding tumor genomic features that may guide treatment for advanced cancer patients, even as experts continue working on strategies for interpreting, evaluating, and communicating such findings in a clinical context.